Key result
Three inactivated Enterovirus A71 vaccines are licensed in China while recombinant options remain under development.
Why the study?
Enterovirus A71 is a major cause of hand, foot, and mouth disease and can lead to neurological complications and death, making vaccination the most efficient control strategy.
This review highlights the current landscape of EV-A71 vaccines, noting three licensed inactivated vaccines and ongoing development of novel vaccine types.
EV-A71 vaccination options remain limited to China; leaves open global advancement of VLP and recombinant platforms.
Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) conducted a review in Enterovirus A71 infection. Enterovirus A71 vaccines was evaluated. Enterovirus A71 vaccines currently include three inactivated, whole-virus vaccines licensed in China, while virus-like particles and recombinant VP1 vaccines remain under development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: